CLINICAL STUDY

T-cell mediated autoimmunity to the insulinoma-associated protein 2 islet tyrosine phosphatase in type 1 diabetes mellitus

Francesco Dotta1, Sabrina Dionisi1, Vissia Viglietta1, Claudio Tiberti1, Maria Cristina Matteoli2, Marco Cervoni3, Carla Bizzarri4, Giovanni Marietti4, Manuela Testi5, Giuseppe Multari3, Lucio Lucentini2 and Umberto Di Mario1

1Department of Endocrinology, University ‘La Sapienza’, Rome, Italy, 2Ospedale ‘Bambino Gesù’, Palidoro, Italy, 3Department of Pediatrics, University ‘La Sapienza’, Rome, Italy, 4Department of Pediatrics, University Cattolica S. Cuore, Rome, Italy and 5Immunohematology Unit, Section on Molecular Biology, Centro Nazionale Trasfusioni Sangue, Croce Rossa Italiana, Rome, Italy

(Correspondence should be addressed to F Dotta, c/o D.E.M. Foundation, Largo Marchiafava 1, 00161, Rome, Italy)

Abstract

The target molecules of the T-cell response in type 1 diabetes, despite their pathogenic importance, remain largely uncharacterized, especially in humans. Interestingly, molecules such as insulin and glutamic acid decarboxylase (GAD) have been shown to be a target not only of autoantibodies, but also of autoreactive T-lymphocytes both in man and in the non-obese diabetic (NOD) mouse. In the present study we aimed to determine the existence of a specific T-cell response towards the insulinoma-associated protein 2 (IA-2) islet tyrosine phosphatase, a recently identified autoantigen which is the target of autoantibodies strongly associated with diabetes development. Human recombinant IA-2 produced in Escherichia coli, was tested for its reactivity with peripheral blood lymphocytes obtained from 16 newly diagnosed type 1 diabetic patients and from 25 normal controls, 15 of whom were HLA-DR-matched. A T-cell proliferation assay was performed in triplicate employing freshly isolated cells in the absence or in the presence of the antigen to be tested (at two different concentrations: 2 μg/ml and 10 μg/ml). A specific T-cell proliferation (defined as a stimulation index (S.I.) $\geq 3$) was observed against IA-2 used at a concentration of 10 μg/ml (but not of 2 μg/ml) in 8/16 diabetic patients, in 1/15 HLA-DR-matched control subjects ($P < 0.01$ by Fisher exact test) and in 0/10 of the remaining normal individuals. A statistically significant difference ($P < 0.003$ by Mann-Whitney U test) was also observed in S.I. values between patients (3.1 ± 1.4) and HLA-DR-matched controls (1.7 ± 0.54) employing IA-2 at a concentration of 10 μg/ml. However, when IA-2 was used at a concentration of 2 μg/ml, the difference in S.I. between patients (1.65 ± 0.8) and controls (1.0 ± 0.3) did not reach statistical significance. In conclusion, these data show the presence of a specific, dose-dependent T-lymphocyte response against the IA-2 islet tyrosine phosphatase at the onset of type 1 diabetes. Consequently, this molecule appears to be a target not only at the B-lymphocyte but also at the T-lymphocyte level, reinforcing the potential pathogenic role of this autoantigen in the islet destructive process.

European Journal of Endocrinology 141 272–278

Introduction

A number of studies (1, 2) have clearly indicated that the progressive autoimmune islet beta cell destruction leading to insulin-dependent (type 1) diabetes mellitus (IDDM) is a T-lymphocyte-mediated event. However, despite the pathogenic importance of the T-cell response in type 1 diabetes, the target molecules of autoreactive T-cells remain largely uncharacterized, especially in humans. Autoantigens so far identified in autoimmune diabetes have been discovered from disease-associated autoantibodies (3, 4) which, although representing important tools for the prediction of future diabetes development, have no pathogenic significance since they do not directly cause any islet damage. Interestingly, molecules such as insulin (5) and glutamic acid decarboxylase (GAD) (6) have been shown to be the target not only of autoantibodies, but also of autoreactive T-lymphocytes both in man and in an animal model of autoimmune diabetes such as the non-obese diabetic (NOD) mouse (7). In addition to insulin and GAD, other molecules expressed in beta-cell secretory granules and mitochondria (8) with a molecular weight around 38 kDa may be important autoantigens in the T-cell response associated with type 1 diabetes.

In the present study we aimed to investigate the existence of a specific T-cell response towards the insulinoma-associated protein 2 (IA-2) islet tyrosine phosphatase, an autoantigen which is the target of
autoantibodies highly associated to diabetes development (9, 10). To this end, human recombinant IA-2 produced in Escherichia coli, was tested for its reactivity with peripheral blood lymphocytes obtained from newly diagnosed type 1 diabetic patients and from HLA-DR-matched normal control individuals.

Materials and methods

Patients
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Hypaque (Sigma, St Louis, MO, USA) density centrifugation from heparinized blood obtained from (i) sixteen newly diagnosed type 1 diabetic patients within one week of the diagnosis (8 males and 8 females, age range 3.5–37 years); according to HLA-DR typing, 3 subjects were DR3/4, 1 was DR3/3, 1 was DR4/4, 4 were DR4/x, 5 were DR3/x. 1 was DR15/12 and one could not be typed for technical reasons, and (ii) twenty-five normal control subjects with no family history for type 1 diabetes matched for sex and age with group (i) patients, comprising a subgroup of 15 individuals HLA-DR-matched with 15 type 1 diabetic subjects.

All subjects were studied for the presence of the following diabetes-associated autoantibodies: anti-insulin (insulin autoantibodies (IAA)), anti-GAD-65 (GAD-65 autoantibodies (GAA)) and anti-IA-2/ICA512bdc islet protein.

HLA-DR typing
HLA-DR molecular typing was performed using a PCR/SSP method. Briefly, high molecular weight DNA, extracted from EDTA-frozen blood samples by a salting out technique, was amplified employing a set of 24 primer solutions containing DRB allele- and group-specific primers. The PCR-amplified DNA fragments were separated by agarose gel electrophoresis and visualized by ethidium bromide staining. The absence or the presence of a specific amplification product defined the specificity of the sample.

Determination of anti-insulin autoantibodies
The presence of IAA has been analyzed employing a competitive fluid phase radioimmunoassay as previously described (11).

Determination of GAD-65 autoantibodies
GAA were measured in triplicate by radioassay, using in vitro transcribed and translated recombinant human GAD (65 kDa isofrom) followed by precipitation with protein A-sepharose (12). The interassay coefficient of variation in our laboratory is 6.5%. The results are expressed as an index calculated from the counts per minute for the test sample and the positive and negative control samples.

Determination of anti-ICA512bdc autoantibodies
ICA512bdc autoantibodies were measured in duplicate using an assay format similar to that for GAA but with in vitro transcribed and translated ICA512bdc (13). The interassay coefficient of variation is 11.7%. ICA512bdc is a new construct that includes amino acid residues 256 through 937 for the originally described ICA512, and amino acids 1 through 979 for the full-length IA-2 molecule). The results are expressed as an index calculated from the counts per minute for the test sample and the positive and negative control samples.

Preparation of the IA-2 molecule
cDNA representing the full-length open reading frame for human IA-2, cloned into the vector pGEM-4Z (Promega, Madison, WI, USA), was expressed as a fusion protein with a biotin-labeled tag sequence and purified on streptavidine agarose as previously described (14).

T-cell proliferation assay
A T-cell proliferation assay was performed in triplicate in 96-well round bottom plates (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) employing freshly isolated PBMC at a concentration of 150 000 cells/well, using RPMI 1640 (Sigma) containing 10% human autologous serum. After incubation for 72 h at 37°C in the absence or in the presence of the antigen to be tested (two different IA-2 concentrations were used: 2 μg/ml and 10 μg/ml), 1 μCi/well [3H]thymidine (Amersham International, Amersham, Bucks, UK) was added and left to incubate for 16 h, followed by determination of thymidine incorporation by liquid scintillation counting. Tetanus toxoid (Calbiochem, San Diego, CA, USA) at a concentration of 2.5 μg/ml and phytohemagglutinin (PHA) (Difco, Detroit, MI, USA) at a concentration of 20 μg/ml were used as positive controls for antigen-specific and aspecific T-cell stimulation respectively. A specific T-cell proliferation was defined as a stimulation index (S.I.) ≥ 3, calculated as the ratio between c.p.m. PBMC in the presence of the antigen and c.p.m. PBMC in medium alone. In addition, the first 8 patients and 9 controls were tested for T-cell reactivity in a ‘blind’ manner (without knowing the antigen preparation) as part of the First Workshop on Autoreactive T Cells in IDDM. In this workshop T-cell reactivity towards a panel of different antigens such as insulin, GAD-65, casein A1 and A2, p69, p277 and C-peptide was tested.

Statistical analysis
Mann-Whitney U test was used to compare the T-cell responses against IA-2 among the different groups of patients. Fisher’s exact test with Yates correction was
used to compare the frequencies of a positive T-cell response in the different groups of patients. Simple regression analysis was utilized to correlate the T-cell response against IA-2 with a number of parameters such as age, IAA, GAA and ICA512bdc autoantibody levels.

**Results**

**Autoantibodies (Table 1)**

Among the 16 newly diagnosed type 1 diabetic patients studied, 10 (62.5%) were IAA positive, 10 (62.5%) were GAA positive and 11 (68.8%) were ICA512bdc positive. All normal controls tested were negative for IAA, GAA and ICA512bdc.

**T-cell response against IA-2**

A specific T-cell proliferation was observed (Fig. 1) against IA-2 used at a concentration of 10 μg/ml in 8/16 diabetic patients, in 1/15 HLA-DR-matched control subjects (P = 0.01 by Fisher exact test) and in 0/10 normal individuals not expressing DR3 or DR4 (P < 0.001 by Fisher exact test). The only normal control with a positive T-cell response against IA-2 was DRB1*03–15. In addition, a statistically significant difference (P = 0.003 by Mann-Whitney U test) was found in the frequency of a specific T-cell response between newly diagnosed type 1 diabetic patients (IDDM) and HLA-DR-matched normal control subjects (NC-HLA) (P = 0.01), and between type 1 diabetic patients and HLA-DR-unmatched (not DR3 nor DR4) normal control subjects (NC) (P < 0.001). Asterisks indicate those subjects tested in a 'blind' manner in terms of antigen preparation.

![Figure 1 T-cell reactivity against IA-2 in the different groups studied.](image-url)

The stimulation index is calculated as the ratio between c.p.m. PBMC in the presence of the antigen and c.p.m. PBMC in medium alone. The horizontal line represents the limit of positivity (S.I. ≥ 3) for T-cell reactivity. A statistically significant difference (by Fisher exact test) was found in the frequency of a specific T-cell response between newly diagnosed type 1 diabetic patients (IDDM) and HLA-DR-matched normal control subjects (NC-HLA) (P = 0.01), and between type 1 diabetic patients and HLA-DR-unmatched (not DR3 nor DR4) normal control subjects (NC) (P < 0.001). Asterisks indicate those subjects tested in a 'blind' manner in terms of antigen preparation.

### Table 1: Characteristics of new onset type I diabetic patients studied.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>IAA† (nU/ml)</th>
<th>GAA‡ (index)</th>
<th>ICA512bdc§ (index)</th>
<th>HLA-DR</th>
<th>IA-2 T-cell (S.I.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12</td>
<td>0.9</td>
<td>0.287</td>
<td>1.194</td>
<td>DRB1*03-04</td>
<td>6.7</td>
</tr>
<tr>
<td>2</td>
<td>11.5</td>
<td>1707</td>
<td>0.001</td>
<td>0.644</td>
<td>DRB1*01-04</td>
<td>4.5</td>
</tr>
<tr>
<td>3</td>
<td>12.5</td>
<td>192</td>
<td>0.093</td>
<td>0.001</td>
<td>DRB1*15-12</td>
<td>4.4</td>
</tr>
<tr>
<td>4</td>
<td>16</td>
<td>5.5</td>
<td>0.827</td>
<td>0.84</td>
<td>DRB1*03-15</td>
<td>3.8</td>
</tr>
<tr>
<td>5</td>
<td>3.5</td>
<td>76.1</td>
<td>0.039</td>
<td>0.227</td>
<td>N.D.</td>
<td>3.5</td>
</tr>
<tr>
<td>6</td>
<td>4</td>
<td>51.7</td>
<td>0.001</td>
<td>0.001</td>
<td>DRB1*03-16</td>
<td>3.4</td>
</tr>
<tr>
<td>7</td>
<td>10</td>
<td>89</td>
<td>0.383</td>
<td>0.391</td>
<td>DRB1*03</td>
<td>3.2</td>
</tr>
<tr>
<td>8</td>
<td>15</td>
<td>1</td>
<td>0.376</td>
<td>0.03</td>
<td>DRB1*01-04</td>
<td>3.1</td>
</tr>
<tr>
<td>9</td>
<td>3.5</td>
<td>784</td>
<td>0.007</td>
<td>0.004</td>
<td>DRB1*01-03</td>
<td>2.7</td>
</tr>
<tr>
<td>10</td>
<td>12</td>
<td>1174</td>
<td>0.388</td>
<td>0.001</td>
<td>DRB1*03-04</td>
<td>2.5</td>
</tr>
<tr>
<td>11</td>
<td>8.5</td>
<td>135</td>
<td>0.713</td>
<td>1.117</td>
<td>DRB1*04-15</td>
<td>1.92</td>
</tr>
<tr>
<td>12</td>
<td>12</td>
<td>6.2</td>
<td>0.001</td>
<td>0.018</td>
<td>DRB1*03-04</td>
<td>1.9</td>
</tr>
<tr>
<td>13</td>
<td>11</td>
<td>231</td>
<td>0.068</td>
<td>0.565</td>
<td>DRB1*01-04</td>
<td>1.9</td>
</tr>
<tr>
<td>14</td>
<td>3.5</td>
<td>87.2</td>
<td>0.162</td>
<td>0.001</td>
<td>DRB1*03-11</td>
<td>1.5</td>
</tr>
<tr>
<td>15</td>
<td>10</td>
<td>13</td>
<td>0.001</td>
<td>0.08</td>
<td>DRB1*04</td>
<td>1.5</td>
</tr>
<tr>
<td>16</td>
<td>37</td>
<td>1</td>
<td>0.352</td>
<td>0.001</td>
<td>DRB1*03-10</td>
<td>0.9</td>
</tr>
</tbody>
</table>

† Values above 39 have been considered as positive. ‡ An index above 0.032 has been considered as positive. § An index above 0.071 has been considered as positive.

N.D., not determined.
HLA-DR3 or -DR4 positive normal controls ($P=0.23$ by Mann-Whitney U test).

In order to determine the dose dependency of the T-cell response against IA-2, the protein was used at a concentration of 2 $\mu$g/ml in a subset of individuals (8 new onset type 1 diabetic patients and 9 normal controls). In this case (Fig. 2), the S.I. observed in the 8 type 1 diabetic patients was $1.65 \pm 0.8$, compared with $3.0 \pm 1.5$ when the antigen was used at 10 $\mu$g/ml ($P=0.015$ by Wilcoxon test for paired data), suggesting the dose dependency of the T-cell response against this antigen. In addition, the difference in S.I. between patients ($1.65 \pm 0.8$) and controls ($1.0 \pm 0.3$) did not reach statistical significance. Moreover, no difference in the T-cell reactivity against the other molecules tested in a ‘blind’ manner (Fig. 3) was observed between patients and control subjects.

Finally, no difference was found among the groups of individuals in the T-cell response against tetanus toxoid or PHA (data not shown).

**Correlation between T-cell response against IA-2 and diabetes-associated autoantibodies (Figs 4 and 5)**

No correlation was found between a positive T-cell response against IA-2 and positivity and/or levels of IAA (Fig. 4a), GAA (Fig. 4b) and ICA512bdc (Fig. 4c).
Figure 4 Correlation between T-cell reactivity against IA-2 and levels of (a) IAA, (b) GAA and (c) ICA512bdcAb in new onset IDDM patients. The vertical dashed line represents the limit of positivity (S.I. ≥ 3) for T-cell reactivity. The horizontal dashed line indicates the limit of autoantibody positivity. The continuous line indicates the regression line.
In addition, the T-cell response against IA-2 was not correlated with the age (Fig. 5) or with the sex of the patient.

Discussion

By analyzing the T-cell response against the islet tyrosine phosphatase IA-2 in peripheral blood lymphocytes from newly diagnosed type 1 diabetic individuals and HLA- and non-HLA-DR matched control subjects, we observed reactive T-lymphocytes against this molecule at a higher frequency in type 1 diabetic patients. This T-cell reactivity was dose dependent and did not correlate with age, sex, HLA-DR type nor with the presence of diabetes-associated autoantibodies (Ab), i.e. IAA, GAA and ICA512bdc-Ab. Cellular immune reactivity towards islet molecules such as insulin, GAD, Imogen 38 and other beta-cell components was reported (15–18) in newly diagnosed type 1 diabetic subjects and in autoantibody-positive relatives by studying peripheral blood lymphocytes. As far as the islet tyrosine phosphatase is concerned, to our knowledge no report of T-cell reactivity against the whole human recombinant IA-2 molecule is to date available, while two reports (19, 20) are already published on the ICA512 fragment and on the entire 42 kDa internal domain of the IA-2, showing a prevalence for a positive T-cell response in new onset type 1 diabetic patients and in high risk relatives similar to that which we observed against the whole IA-2 molecule. Differently from the data on the ICA512 fragment which have been generated employing a hybrid molecule with glutathione-S-transferase as fusion protein, in our study the antigen preparation used was represented by the IA-2 molecule alone. The magnitude of the response we observed against IA-2 was lower than that reported towards ICA512; however, this may be due to the shorter incubation (3 days vs 5 days) used in our assay. It should be pointed out that in our study all patients were individually HLA-DR matched to a given normal control. In addition, 8 type 1 diabetic patients and 9 controls were tested in a ‘blind’ manner in terms of antigen preparation. In this way, a significant increase in both frequency and magnitude of T-cell reactivity was observed in patients versus controls, suggesting that the presence of such a reactivity is associated with an ongoing autoimmune response against the pancreatic islet beta-cells, rather than determined by the presence of a diabetes-susceptibility to HLA-DR haplotype itself. No significant correlation between the humoral and cellular immune response against IA-2 has been observed, in parallel with that reported (19, 20) on insulin and on the ICA512 fragment, but in contrast with the data observed on GAD (16).

It should be considered that, at least in some cases, the PBMC proliferative responses might be due to trace bacterial contaminants deriving from the antigen preparation procedures used in this type of study. Anyway, with regard to this aspect, the difference between patients and controls is difficult to explain by this phenomenon; furthermore, another antigen such as GAD-65, although prepared in E. coli, did not show different proliferative responses from type 1 diabetic patients and controls.

In conclusion, these data show that a specific, dose-dependent T-lymphocyte response against the IA-2 islet tyrosine phosphatase is present at the onset of type 1 diabetes, indicating that this molecule represents a target not only at the B-lymphocyte but also at the T-lymphocyte level, reinforcing the potential pathogenic role of this autoantigen in the islet destructive process leading to the disease.
Acknowledgements
The IA-2 molecule tested for T-cell reactivity was kindly provided by Dr M R Christie, King’s College School of Medicine, London, UK. The technical assistance of Paola Cerrone has been greatly appreciated. This work was supported by grants from the National Research Council of Italy (UDM), the Italian Society of Diabetology and the Juvenile Diabetes Foundation (FD), the Italian Ministry of Health (IL) and from the D.E.M. Foundation.

References
16 Harrison LC, Honeyman MC and DeAizpurua HJ. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes. The Lancet 1993 341 1365–1369.